Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.42 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645879 | 1.00 | LMNA (0.49) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL22645881 | 1.00 | LMNA (0.49) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL29321833 | 1.00 | LMNA (0.49) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL19161172 | 1.00 | LMNA (0.49) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL29321926 | 1.00 | LMNA (0.49) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL31065291 | 1.00 | LMNA (0.49) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL18641726 | 1.00 | LMNA (0.49) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL30989590 | 0.99 | LMNA (0.48) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL25037492 | 0.92 | ALDH1A1 (0.50) | LMNAALDH1A1MAPTPRKCAPRKCE | |
| SCHEMBL21845192 | 0.92 | LMNA (0.50) | LMNAALDH1A1MAPTPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4186888-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12404232-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12151995-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017106799-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017070624-A1 | TROPICAL DISEASE VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070613-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070618-A1 | CANCER VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070616-A2 | SEXUALLY TRANSMITTED DISEASE VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | LMNA 1539/4885ALDH1A1 4530/4885MAPT 2478/4885 |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | LMNA 1539/4885ALDH1A1 4530/4885MAPT 2478/4885 |
| US-12151995-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | LMNA 1539/4885ALDH1A1 4530/4885MAPT 2478/4885 |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | LMNA 1539/4885ALDH1A1 4530/4885MAPT 2478/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | LMNA 455/4885ALDH1A1 4429/4885MAPT 2007/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | LMNA 2139/4885ALDH1A1 3662/4885MAPT 4836/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | LMNA 1487/4885ALDH1A1 4755/4885MAPT 4504/4885 |
| US-12404232-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | LMNA 1539/4885ALDH1A1 4530/4885MAPT 2478/4885 |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | LMNA 1539/4885ALDH1A1 4530/4885MAPT 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.